The patent grant removes a key IP overhang and provides a long runway for stenoparib development. Monitor upcoming Phase 2 data readouts in ovarian cancer and SCLC, as well as any partnership or financing announcements given the $20M market cap.
Price Chart
Executive Summary
Allarity Therapeutics announced the USPTO grant of a key U.S. patent covering its stenoparib-specific DRP companion diagnostic, providing exclusivity until April 2042. This strengthens the company's intellectual property position for its lead drug candidate in ovarian cancer and other indications.
Key Facts
- USPTO granted U.S. patent for stenoparib-specific DRP companion diagnostic with term extending to April 2042.
- Patent covers methods for predicting clinical benefit from stenoparib based on gene-expression profiles and selecting patients for treatment.
- Allarity also has patent protection for stenoparib DRP in Europe and Australia into 2039.
- Annual meeting proposals passed including equity plan increase to 2,021,990 shares and approval of share issuance under Tumim Stone Capital agreement.
- Proposal to limit officer liability did not pass.
Financial Impact
No financial figures provided; patent extends commercial exclusivity for stenoparib DRP into 2042, potentially enhancing long-term value if drug is approved.
Risk Factors
- Clinical-stage company with no approved products; stenoparib still requires FDA approval.
- Patent may face third-party challenges or validity proceedings.
- Company may need additional capital to fund ongoing trials and operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-073998 |
| Document: ea029661501ex99-1.htm | 0001213900-26-073998 |
| Document: 0001213900-26-073998-index-headers.html | 0001213900-26-073998 |
| Document: 0001213900-26-073998-index.html | 0001213900-26-073998 |
| Document: 0001213900-26-073998.txt | 0001213900-26-073998 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9150 (−12.02%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 $0.9200 | ▼ −4.67% | ▼ −5.39% | $0.9150 (−5.19%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9150 (−5.51%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9150 (−20.78%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9150 (−21.79%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9150 (−25.00%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9150 (−33.21%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9150 (−31.20%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9150 (−32.72%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9150 (−36.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers